Literature DB >> 11440634

Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway.

N Yokoyama1, N C Reich, W T Miller.   

Abstract

In this study, we report that the tyrosine kinase, Janus kinase 2 (Jak2), associates with the serine/threonine protein phosphatase 2A (PP2A) in 32Dcl3 myeloid progenitor cells. The association between Jak2 and PP2A transiently increases following interleukin-3 (IL-3) stimulation and activation of Jak2. The catalytic subunit of PP2A is tyrosine phosphorylated by Jak2 in vitro and in vivo, resulting in inhibition of phosphatase activity. PP2A also associates with Stat5 in 32Dcl3 cells in an IL-3-dependent manner. Pretreatment of 32Dcl3 cells with okadaic acid (OA), an inhibitor of PP2A, resulted in increased tyrosine phosphorylation and nuclear translocation of Stat5. Our results suggest that PP2A plays a negative regulatory role in regulating the IL-3 signaling pathway via formation of complexes with Jak2 and Stat5.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440634     DOI: 10.1089/107999001750277844

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  15 in total

1.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

Review 3.  Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.

Authors:  Md Nematullah; M N Hoda; Farah Khan
Journal:  Mol Neurobiol       Date:  2017-02-21       Impact factor: 5.590

4.  Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors:  A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

5.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

7.  Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.

Authors:  Jeremy A Ross; Hanyin Cheng; Zsuzsanna S Nagy; Jeffrey A Frost; Robert A Kirken
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

8.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Authors:  Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

9.  Interaction of STAT6 with its co-activator SRC-1/NCoA-1 is regulated by dephosphorylation of the latter via PP2A.

Authors:  Tobias Münz; Claudia M Litterst; Edith Pfitzner
Journal:  Nucleic Acids Res       Date:  2010-12-08       Impact factor: 16.971

10.  Phosphoprotein phosphatase-2A docks to Dishevelled and counterregulates Wnt3a/beta-catenin signaling.

Authors:  Noriko Yokoyama; Craig C Malbon
Journal:  J Mol Signal       Date:  2007-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.